JANUARY 13, 2025--Bristol Myers Squibb CEO Chris Boerner told attendees at the JP Morgan Healthcare Conference on Monday that Cobenfy (xanomeline/trospium chloride) is launching strongly in the US schizophrenia market and holds considerable promise across a number of other indications.
Approved by the FDA in September, Cobenfy has a clear run at building a patient base following AbbVie's confirmation in November that its similar drug emraclidine had failed to deliver positive data in a Phase II study.
Looking to build further on this advantage, Boerner said that the company expects to announce clinical data readouts for Cobenfy in new indications each year until the end of the decade.
In 2025, results from two pivotal-stage studies are expected — in adjunctive schizophrenia (to build on Cobenfy's existing label) and in Alzheimer's disease psychosis. Boerner noted that about half of the six million US patients with Alzheimer's suffer from related psychosis. Most patients are treated with off-label therapies, and there is a considerable level of unmet need, he noted.
BMS is confident in Cobenfy's outlook across different indications thanks to the strength of data already presented in schizophrenia, whilst a cleaner safety profile versus older atypical antipsychotics supports potential combination use, Boerner emphasised.